

Percutaneous coronary intervention


Produced by :

Ali Izadi Amoli, MD, fellowship of interventional cardiology

Introduction

- Percutaneous Coronary Intervention is a minimally invasive nonsurgical procedure performed to improve blood flow in one or more segments of the coronary circulation.
- The first percutaneous coronary angioplasty was performed by the German Cardiologist Andreas Gruentzig on 1977, but the first angioplasty in lower limb arteries was done with Dr. Dotter on 1964.
- Coronary revascularization with PCI primarily involves the use of balloon angioplasty and intracoronary stenting with DES or BMS.

- The first coronary angioplasty with a drug delivery stent system was performed in Buenos Aires in 1999.
- DES reduced the rate of restenosis and target lesion revascularization compared with BMS
- DES: 1. metallic alloy 2.polymer coating (durable or bioabsorbable)
 3.antirestenotic drug





- DES reduced local neointimal hyperplasia.

 DES significantly lower the rate of target lesion revascularization compared BMS.

Type of DES

First generation DES

Sirolimus-eluting stents Cypher® Stent (Medtronic, Inc, Minneapolis, MN) Paclitaxel-eluting stents Taxus®

Second generation DES

Zotarolimus-eluting stents Endeavor®

Everolimus-eluting stents Xience V[®] Everolimus Eluting Coronary Stent (Abbott Laboratories, Abbott Park, IL) Promus[®] Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation, Natick, MA)

TABLE 1 Evolution of drug-eluting stents

First generation

Nonbiodegradable (ie, durable) polymer-based thick strut Sirolimus- or paclitaxel-eluting stents

Second generation

Nonbiodegradable (ie, durable) polymer-based thin strut "Limus"-eluting stent (eliminated paclitaxel)

Third generation

Biodegradable polymer-based thick or thin strut "Limus"-eluting stent

Third generation "B"

Polymer-free strut "Limus"-eluting stents

Fourth generation

Bioresorbable, thick/thin strut "Limus"-eluting vascular scaffolds (PLLA or magnesium)

"Limus" drugs: biolimus, everolimus, myolimus, novolimus, sirolimus, zotarolimus.


PLLA = poly-L-lactic acid

Primary PCI

- STEMI is defined by symptoms of myocardial ischemia associated with persistent electrocardiographic evidence of ST elevation and subsequent elevation of biologic markers of myocardial necrosis.
- ST elevation in the absence of either left bundle branch block (LBBB) or left ventricular (LV) hypertrophy is defined as new ST elevation of at least 2 mm in men or 1.5 mm in women in at least two contiguous leads.
- STEMI is inexorably linked to sudden cardiac death. Indeed, some 70% of deaths attributable to coronary heart disease occur with out of-hospital arrest.

- Primary PCI is generally preferable to fibrinolytic therapy.
- Primary PCI, when successful, also results in early hospital discharge and return to activities.
- Potential adverse effects of primary PCI include arterial access site complications and contrast agent— and antithrombotic-related complications.

Primary PCI






TABLE 52G-1 Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

	COR	LEVEL OF EVIDENCE
Ischemic symptoms <12 hr	I	А
Ischemic symptoms <12 hr and contraindications to fibrinolytic therapy irrespective of delay in time after FMC	I.	В
Cardiogenic shock or acute severe HF irrespective of delay in time after the onset of MI	I.	В
Evidence of ongoing ischemia 12-24 hr after the onset of symptoms	lla	В

Absolute Contraindications

Any previous intracranial hemorrhage Known structural cerebral vascular lesion Known malignant intracranial neoplasm Ischemic stroke within 3 months (except ischemic stroke within 4.5 hours) Suspected aortic dissection Active bleeding or bleeding diathesis Significant closed-head or facial trauma within 3 months Intracranial or intraspinal surgery within 2 months Severe uncontrolled hypertension (not responsive to emergency therapy) For streptokinase, previous treatment within 6 months

Relative Contraindications

History of chronic, severe, poorly controlled hypertension Significant hypertension at initial evaluation (systolic blood pressure >180 mm Hg, diastolic blood pressure >110 mm Hg) History of ischemic stroke >3 months Dementia Known intracranial pathology not covered in Absolute Contraindications Traumatic or prolonged cardiopulmonary resuscitation (>10 minutes) Major surgery within 3 weeks Recent internal bleeding (within 2-4 weeks) Noncompressible vascular puncture Pregnancy Active peptic ulcer Oral anticoagulant therapy


TABLE 52G-6 Indications for Transfer for Angiography after Fibrinolytic Therapy


	COR	LEVEL OF EVIDENCE
Cardiogenic shock or acute severe heart failure that develops after initial evaluation	I.	В
Intermediate- or high-risk findings on predischarge noninvasive ischemia testing	I.	В
Spontaneous or easily provoked myocardial ischemia	I.	C
Failed reperfusion or reocclusion after fibrinolytic therapy	lla	В
Stable* patients after successful fibrinolysis, before discharge and ideally between 3 and 24 hr	lla	В


Rescue PCI & Elective PCI

TABLE 52G-7 Indications for Percutaneous Coronary Intervention on an Infarct Artery in Patients Who Were Managed with Fibrinolytic Therapy or Who Did Not Receive Reperfusion Therapy

	COR	LEVEL OF EVIDENCE
Cardiogenic shock or acute severe heart failure	I.	В
Intermediate- or high-risk findings on predischarge noninvasive ischemia testing	1	С
Spontaneous or easily provoked myocardial ischemia	1	C
Patients with evidence of failed reperfusion or with reocclusion after fibrinolytic therapy (as soon as possible)	lla	В
Stable* patients after successful fibrinolysis, ideally between 3 and 24 hr	lla	В
Stable* patients >24 hr after successful fibrinolysis	llb	В
Delayed PCI on a totally occluded infarct artery >24 h after STEMI in stable patients	III: No benefit	В







Iranian 🗆 Not Iranian	سال ئولد:			- / متعاره کذرناه :
تاريخ ټولد:/ ۱۳	جنس: 🗆 مرد 🗆 زن		نام خانوادگی :	
	Demogra	phic Data		مراجعه بيمار:
ماره پرونده : بلیت PPCI	ث جاع از بیمارستان بدون قا		بيمارستان توسط EMS	انتقال بد اور ان
1	بار بستری در بیمارستان	~	ار	مراجعه مستقيم بيه
	Time]	Intervals		
Onset of Symptoms	(yyyy/mm/d	ld)//	(hh/mm)/	
First Medical Contact	(yyyy/mm/d	d)/ /	(hh/mm)/	
Admission Time (Door Time)	(yyyy/mm/d	ld)//	(hh/mm)/	
Device Time	(yyyy/mm/d	a)///	(hh/mm)	
STEMI ECG : (YYYY	/mm/dd)//	(hh/mm)		
	/mm/dd)//			
(11110) (333)		(menun)		
Arrival at Cath lah · (youy	/mm/dd) / /	(hh/mm)	7	
Arrival at Cath lab : (yyyy	/mm/dd) /			
		(hl/mm) Jab Data		
Arrival at Cath lab : (yyyy - Initial Reperfusion Therapy : O Primary PCI				
- Initial Reperfusion Therapy : O Primary PCI O Rescue PCI				
- Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG				
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment 				
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI 	Cath I	Lab Data		
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : 	Cath I	Lab Data		
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI 	Cath I	Lab Data		
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : Graft Diagonal 	Cath I	Lab Data		
 Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : Graft	Cath I	Lab Data		
- Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : Graft	Cath I	Lab Data	□ LCX □ PDA	
- Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : Graft	Cath I Ca	Lab Data	□ LCX □ PDA	
- Initial Reperfusion Therapy : O Primary PCI O Rescue PCI O Urgent CABG O Medical Treatment O Unsuccessful P.PCI Infarct related artery (IRA) : Graft □ Diagonal Initial TIMI flow grade in IRA Final TIMI flow grade in IRA Cor Condition at discharge: □ Alive Ejection fraction at discharge: □	Cath I Ca	Lab Data	□ LCX □ PDA	□ R(□ P







P2Y₁₂ Inhibitors

Loading Doses

	 Clopidogrel: 600 mg as early as possible or at the time of PCI 	1	В
	 Prasugrel: 60 mg as early as possible or at the time of PCI 	I	В
	 Ticagrelor: 180 mg as early as possible or at the time of PCI 	I	В
	Maintenance Doses and Duration of Therapy		
	DES placed: Continue therapy for 1 year with		
	Clopidogrel: 75 mg daily	1	В
	Prasugrel: 10 mg daily	1	В
	 Ticagrelor: 90 mg twice a day* 	1	В
	BMS [†] placed: Continue therapy for 1 year with		
	Clopidogrel: 75 mg daily	1	В
	Prasugrel: 10 mg daily	1	В
	 Ticagrelor: 90 mg twice a day* 	1	В
6	DES placed:		
	 Clopidogrel, prasugrel, or ticagrelor* continued beyond 1 year 	llb	С

III: Harm

B

• Patients with STEMI and previous stroke or TIA: prasugrel

	COR	LEVEL OF EVIDENCE
Anticoagulant Therapy		1
• UFH		
 With a GP IIb/IIIa receptor antagonist planned: 50- to 70-unit/kg IV bolus to achieve therapeutic ACT[*] 	I	С
 With no GP IIb/IIIa receptor antagonist planned: 70- to 100-unit/kg bolus to achieve a therapeutic ACT[§] 	I	С
 Bivalirudin: 0.75-mg/kg IV bolus, then 1.75-mg/kg/hr infusion with or without previous treatment with UFH. An additional bolus of 0.3 mg/kg may be given if needed 	I	В
 Reduce the infusion to 1 mg/kg/hr with estimated an CrCl <30 mL/min 		
 Preferred over UFH with a GP IIb/IIIa receptor antagonist in patients at high risk for bleeding 	lla	В
 Fondaparinux: not recommended as the sole anticoagulant for primary PCI 	III: Harm	В

Intraveneurs Chronistein IIb/IIIa Recenter Antagonists in Conjunction with Unfractionated He	enaria or Dhalinudia in	Colocted Dationts
Intravenous Glycoprotein IIb/IIIa Receptor Antagonists in Conjunction with Unfractionated He	epann or bivailrudin in	selected ratients
 Abciximab: 0.25-mg/kg IV bolus, then 0.125 µg/kg/min (maximum, 10 µg/min) 	lla	А
 Tirofiban (high bolus dose): 25-µg/kg IV bolus, then 0.15 µg/kg/min 	lla	В
 In patients with CrCl <30 mL/min, reduce the infusion by 50% 		
 Eptifibatide (double bolus): 180-µg/kg IV bolus, then 2 µg/kg/min; a second 180-µg/kg bolus is administered 10 min after the first bolus 	lla	В
 In patients with CrCl < 50 mL/min, reduce the infusion by 50% 		
Avoid in patients on hemodialysis		
 Pre-catheterization laboratory administration of IV GP IIb/IIIa receptor antagonist 	llb	В
Intracoronary abciximab: 0.25-mg/kg bolus	llb	В
 Eptifibatide (double bolus): 180-µg/kg IV bolus, then 2 µg/kg/min; a second 180-µg/kg bolus is administered 10 min after the first bolus In patients with CrCl < 50 mL/min, reduce the infusion by 50% Avoid in patients on hemodialysis Pre-catheterization laboratory administration of IV GP IIb/IIIa receptor antagonist 	llb	В

Vascular Access

- Femoral & radial
- − In femoral access \rightarrow INR < 1.8
- − In Radial Access \rightarrow INR < 2.2

Rival Trial

	FEMORAL (N = 3514)	RADIAL (N = 3507)	P VALUE
Composite of death, MI, stroke, or non- CABG-related major bleeding at 30 days*	4.0%	3.7%	0.50
Death at 30 days	1.5%	1.3%	0.47
MI at 30 days	1.9%	1.7%	0.65
Stroke at 30 days	0.4%	0.6%	0.30
PCI success	95.2%	95.4%	0.83
Access site crossover	2.0%	7.6%	<0.0001
Major vascular complications	3.7%	1.4%	<0.0001
Access site major bleeding	0.3%	0.2%	Not provided
Symptomatic radial occlusion	NA	0.2%	NA
Procedure time (min)	35	34	0.62
Fluoroscopy time (min)	8.0	9.3	<0.0001
Contrast volume (mL)	180	181	0.87
Patient prefers radial access for next procedure	50.7%	90.2%	<0.0001

Vascular Access Complications

 Vascular access site complications occur after 3% to 7% of femoral PCIs and lead to significantly increased length of hospital stay, total cost, and morbidity and mortality. Complications range from relatively minor access site hematomas, to life-threatening retroperitoneal bleeding requiring emergency blood transfusion, to damage to the vasculature necessitating prompt surgical intervention

Predisposing factor :

older age, female sex, larger vascular sheath size, low body mass index, renal insufficiency, and degree of anticoagulation during the procedure

COMPLICATION	SCAI REGISTRY RISK (%)
Mortality	0.11
Myocardial infarction	0.05
Cerebrovascular accident	0.07
Arrhythmias	0.38
Vascular complications	0.43
Contrast agent reaction	0.37
Hemodynamic complications	0.26
Perforation of heart chamber	0.03
Other complications	0.28
Total of major complications	1.70

6

6

V

V


- In femoral access , sheath removal is done when ACT < 180
- In radial access , sheath removal is done after procedure and TR band is used
- Cardiac monitoring
- ECG
- Evaluation for complication after PCI like hematoma , bleeding from access site , retroperitoneal hemorrhage , stroke , chest pain , arrhythmia
- − After Primary PCI \rightarrow CBR until 12 h except in unstable homodynamic
- NPO or clear liquid diet until 4 12 h then Po low salt low fat

Post PCI Care

- Chest pain after PCI is relatively common.
- Chest pain after PCI, may occur as a result of acute or subacute stent thrombosis, residual dissections, plaque prolapse, side branch occlusion, or thrombus at the treatment site

TABLE 55G-5 ACC/AHA Postprocedure Recommendations for Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention³

INDICATION	CLASS	RECOMMENDATION	LOE
Aspirin	Class I Class IIa	After PCI, use of aspirin should be continued indefinitely After PCI, it is reasonable to use ASA, 81 mg/day, in preference to higher maintenance doses	A B
P2Y ₁₂ inhibitors: STEMI and unstable angina/NSTEMI	Class I	In patients receiving a stent during PCI for ACS, P2Y ₁₂ inhibitor therapy should be given for at least 12 months. Options include clopidogrel, 75 mg/day; prasugrel, 10 mg/day; or ticagrelor, 90 mg twice daily	В
	Class I	In patients receiving a DES during PCI for a non-ACS indication, clopidogrel, 75 mg/day, should be given for at least 12 months if not at high risk for bleeding	В
		In patients receiving a BMS during PCI for a non-ACS indication, clopidogrel, 75 mg/day, should be given for a minimum of 1 month and ideally up to 12 months (unless the patient is at increased risk for bleeding, in which case it should be given for a minimum of 2 weeks)	С
		PPIs should be used in patients with a history of previous GI bleeding who require DAPT	С
	Class IIa	If the risk for morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y ₁₂ inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of P2Y ₁₂ inhibitor therapy is reasonable	С
		Use of PPIs is reasonable in patients with an increased risk for GI bleeding who require DAPT	С
	Class IIb	Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 months may be considered in patients undergoing placement of a DES	C
	Class III no benefit	Routine use of a PPI is not recommended for patients at low risk for GI bleeding	C



- Elective PCI without on site surgery \rightarrow Class IIb

